| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Myosin Light Chain Kinase (MLCK), Akt Kinase, and STIM1 (Inhibitor)
|
|---|---|
| ln Vitro |
Cardiomyocyte viability is not affected by ML9 (free base) (0-100 μM; 0-24 hours), while cell death is strongly induced by ML9 (50-100 μM) [2]. STIM1 protein levels are lowered by around 42% and cleaved caspase-3 levels are markedly increased by ML9 (free base) (50 μM; 1-4 hours) [2].
ML-9 is a selective and potent inhibitor of Akt kinase and MLCK. It inhibits MLCK with a Ki of 4 μM, PKA with a Ki of 32 μM, and PKC with a Ki of 54 μM. ML-9 also inhibits stromal interaction molecule 1 (STIM1) activity and store-operated Ca2+ entry. The compound induces autophagy by stimulating autophagosome formation and inhibiting their degradation. |
| ln Vivo |
ML-9 has been studied in vivo for its effects on smooth muscle contraction, vascular tone, and cancer. The compound inhibits store-operated Ca2+ entry and affects endoplasmic reticulum Ca2+ homeostasis. In animal models, ML-9 reduces blood pressure and inhibits smooth muscle contraction.
|
| Enzyme Assay |
MLCK inhibition assays for ML-9 use purified MLCK and MLC as substrate. The assay measures [32P]-ATP incorporation into MLC. ML-9 is incubated with MLCK, MLC, calmodulin, CaCl2, and [γ-32P]-ATP. For Akt kinase inhibition, recombinant Akt and a peptide substrate are used with [γ-32P]-ATP.
|
| Cell Assay |
Cell viability assay[1]
Cell Types: Neonatal rat ventricular myocytes (NRVM) Cell Tested Concentrations: 0, 10, 50 and 100 μM Incubation Duration: 0, 1, 4, 8 and 24 hrs (hours) Experimental Results: Cells at 50–100 μM Vitality reduces concentration. Apoptosis analysis [1] Cell Types: Neonatal rat ventricular myocytes (NRVM) Cell Tested Concentrations: 50 μM Incubation Duration: 0, 1, 4, 8 hrs (hours) Experimental Results: Induction of cardiomyocyte death via necrosis and apoptosis. Cell-based assays for ML-9 include measurement of MLC phosphorylation by Western blotting, assessment of autophagy by monitoring LC3-II conversion and autophagosome formation, and evaluation of store-operated Ca2+ entry using fluorescent calcium indicators. Cell viability assays assess cytotoxic effects. |
| Animal Protocol |
In vivo studies with ML-9 include evaluation of effects on blood pressure in hypertensive rat models, smooth muscle contraction in tracheal or vascular ring preparations, and anti-tumor activity in prostate cancer xenograft models. ML-9 is administered intravenously or intraperitoneally.
|
| References |
|
| Additional Infomation |
1-[(5-chloro-1-naphthyl)sulfonyl]-1,4-diazacycloheptane is a naphthalene compound and also a sulfonic acid derivative.
|
| Molecular Formula |
C15H17CLN2O2S
|
|---|---|
| Molecular Weight |
324.82568
|
| Exact Mass |
324.07
|
| CAS # |
110448-31-2
|
| Related CAS # |
ML-9;105637-50-1
|
| PubChem CID |
4217
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.824
|
| tPSA |
57.79
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
21
|
| Complexity |
451
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=S(N1CCNCCC1)(C2=C3C=CC=C(C3=CC=C2)Cl)=O
|
| InChi Key |
OZSMSRIUUDGTEP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H17ClN2O2S/c16-14-6-1-5-13-12(14)4-2-7-15(13)21(19,20)18-10-3-8-17-9-11-18/h1-2,4-7,17H,3,8-11H2
|
| Chemical Name |
1-((5-chloronaphthalen-1-yl)sulfonyl)-1,4-diazepane
|
| Synonyms |
ML-9 ML9 ML 9
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0785 mL | 15.3927 mL | 30.7853 mL | |
| 5 mM | 0.6157 mL | 3.0785 mL | 6.1571 mL | |
| 10 mM | 0.3079 mL | 1.5393 mL | 3.0785 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.